FSAI National Medical Research Center for Children's Health of the Russian Federation Ministry of Health, Moscow 119991, Russia.
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow 119991, Russia.
Genes (Basel). 2023 Oct 28;14(11):2016. doi: 10.3390/genes14112016.
Fabry disease (FD) is a rare hereditary multisystem disease caused by variants of the gene. Determination of gene variants and identification of genotype-phenotype correlations allow us to explain the features of FD associated with predominant damage of one or another system, both in the classical and atypical forms of FD, as well as in cases with late manifestation and involvement of one of the systems.
The study included 293 Russian patients with pathogenic variants of the gene, which were identified as a result of various selective screening programs. Screening was carried out for 48,428 high-risk patients using a two-step diagnostic algorithm, including the determination of the concentration of the biomarker lyso-Gb3 as a first-tier test. Screening of atypical FD among patients with HCM was carried out via high-throughput sequencing in another 2427 patients.
102 (0.20%) cases of FD were identified among unrelated patients as a result of the study of 50,855 patients. Molecular genetic testing allowed us to reveal the spectrum and frequencies of 104 different pathogenic variants of the gene in 293 examined patients from 133 families. The spectrum and frequencies of clinical manifestations in patients with FD, including 20 pediatric patients, were described. Correlations between the concentration of the lyso-Gb3 biomarker and the type of pathogenic variants of the gene have been established. Variants identified in patients with early stroke were described, and the association of certain variants with the development of stroke was established.
The results of a large-scale selective FD screening, as well as clinical and molecular genetic features, in a cohort of 293 Russian patients with FD are described.
法布里病(FD)是一种罕见的遗传性多系统疾病,由 基因的变异引起。 基因变异的确定和基因型-表型相关性的鉴定使我们能够解释与一个或另一个系统主要损伤相关的 FD 特征,无论是在 FD 的经典和非典型形式中,还是在表现较晚且一个系统受累的情况下。
该研究纳入了 293 名携带 基因致病性变异的俄罗斯患者,这些变异是通过各种选择性筛查计划确定的。对 48428 名高危患者进行了两步诊断算法的筛选,包括作为一线检测的生物标志物溶酶体 Gb3 浓度的测定。对 2427 名 HCM 患者进行了非典型 FD 的高通量测序筛查。
在对 50855 名患者的研究中,共发现 102 例(0.20%)非关联患者的 FD 病例。分子遗传学检测使我们能够在 293 名来自 133 个家族的受检患者中揭示 104 种不同的 基因致病性变异的谱和频率。描述了 FD 患者(包括 20 名儿科患者)的临床表现谱和频率。还建立了溶酶体 Gb3 生物标志物浓度与 基因致病性变异类型之间的相关性。描述了在早期卒中患者中发现的变异,并确定了某些变异与卒中发生的相关性。
描述了大规模选择性 FD 筛查的结果,以及 293 名俄罗斯 FD 患者的临床和分子遗传学特征。